Search For "azd1222"
Updated : 5 months, 2 weeks ago IST
New Delhi [India], November 23 (ANI): Serum Institute of India (SII), CEO, Adar Poonawalla on Monday said that he is delighted to hear that Covidshield, soon to be widely available COVID-19 vaccine, will offer protection up to 90 per cent in one dosage regime and 62 per cent in another.
New Delhi [India], November 23 (ANI): With an efficacy of around 90 per cent positive results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil the vaccine has proved to be highly effective in preventing COVID-19, said AstraZeneca on Monday.
Updated : 6 months, 2 weeks ago IST
London [UK], October 24 (ANI): The clinical trials for the AstraZeneca Oxford coronavirus vaccine -- AZD1222 -- have resumed in the United States after approval by the Food and Drug Administration (FDA), the company said on Friday (local time).